The use of intermediate endpoints in the design of type 1 diabetes prevention trials
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This paper presents a rationale for the selection of intermediate endpoints to be used in the design of type 1 diabetes prevention clinical trials.
Relatives of individuals diagnosed with type 1 diabetes were enrolled on the TrialNet Natural History Study and screened for diabetes-related autoantibodies. Those with two or more such autoantibodies were analysed with respect to increased HbA1c, decreased C-peptide following an OGTT, or abnormal OGTT values as intermediate markers of disease progression.
Over 2 years, a 10% increase in HbA1c, and a 20% or 30% decrease in C-peptide from baseline, or progression to abnormal OGTT, occurred with a frequency between 20% and 41%. The 3- to 5-year risk of type 1 diabetes following each intermediate endpoint was high, namely 47% to 84%. The lower the incidence of the endpoint being reached, the higher the risk of diabetes. A diabetes prevention trial using these intermediate endpoints would require a 30% to 50% smaller sample size than one using type 1 diabetes as the endpoint.
The use of an intermediate endpoint in diabetes prevention is based on the generally held view of disease progression from initial occurrence of autoantibodies through successive immunological and metabolic changes to manifest type 1 diabetes. Thus, these markers are suitable for randomised phase 2 trials, which can more rapidly screen promising new therapies, allowing them to be subsequently confirmed in definitive phase 3 trials.
- Atkinson, MA, Eisenbarth, GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: pp. 221-229 CrossRef
- Diagnosis and classification of diabetes mellitus. Diabetes Care 34: pp. 62-69 CrossRef
- Sosenko, JM, Palmer, JP, Greenbaum, CJ (2006) Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 29: pp. 643-649 CrossRef
- Sosenko, JM, Palmer, JP, Rafkin-Mervis, L (2008) Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 31: pp. 2188-2192 CrossRef
- Study design of the trial to reduce IDDM in the genetically at risk (TRIGR). Pediatr Diabetes 8: pp. 117-137 CrossRef
- Skyler, JS, Krischer, JP, Wolfsdorf, J (2005) Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28: pp. 1068-1076 CrossRef
- Mahon, JL, Sosenko, JM, Rafkin-Mervis, L (2009) The TrialNet natural history study of the development of type 1 diabetes: objectives, design, and initial results. Pediatr Diabetes 10: pp. 97-104 CrossRef
- Kaplan, EL, Meier, P (1958) Nonparametric estimation from incomplete observations. J Amer Statist Assn 53: pp. 457-481 CrossRef
- Greenwood M (1926) The natural duration of cancer. Reports on public health and medical subjects, vol. 33. Her Majesty's Stationery Office, London, pp 1–26
- Fleming, TR (2005) Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 24: pp. 67-78 CrossRef
- The use of intermediate endpoints in the design of type 1 diabetes prevention trials
Volume 56, Issue 9 , pp 1919-1924
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Clinical trial
- Intermediate endpoints
- Type 1 diabetes
- Industry Sectors